Evidence map›Paper›PMID 35869624›Full record

ArticleThe Journal of international medical research2022

The combination of decitabine and aspirin inhibits tumor growth and metastasis in non-small cell lung cancer.

Maoyi Xu, Binbin Song, Xinmei Yang, Na Li

Open access · goldAbstract read
In one paragraph

Article in The Journal of international medical research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
1.9field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Targeting the Epigenetic Landscape for Lung Cancer Treatment.Journal of cellular and molecular medicine · 2025
    Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Maoyi XuDepartment of Oncology, The First Hospital of Jiaxing (The Affiliated Hospital of Jiaxing University), Jiaxing, Zhejiang, PR China.
Binbin SongDepartment of Oncology, The First Hospital of Jiaxing (The Affiliated Hospital of Jiaxing University), Jiaxing, Zhejiang, PR China.
Xinmei YangDepartment of Oncology, The First Hospital of Jiaxing (The Affiliated Hospital of Jiaxing University), Jiaxing, Zhejiang, PR China.
Na LiDepartment of Pathology, Jiaxing Maternity and Child Health Care Hospital, College of Medicine, Jiaxing University, Jiaxing, Zhejiang, PR China.ORCID https://orcid.org/0000-0003-4997-0668
Jiaxing University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveCombination therapy has become the hallmark of lung cancer treatment, as it reduces the dosage intensity of individual drugs while increasing their efficacy. In the current study, we analyzed the combinatorial effect of decitabine and aspirin on non-small cell lung cancer (NSCLC) cell growth.

methodsIn this study, we investigated the combinatorial effect of decitabine and aspirin by MTT, colony formation, and Transwell assays. We also explored the underlying molecular mechanism

resultsThe combination of decitabine and aspirin regulated cell viability and migration

conclusionThe combined administration of decitabine and aspirin significantly reduced tumor growth compared with single-agent treatment and the control

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsAspirinbeta CateninCell Line, TumorCell MovementCell ProliferationDecitabineHumansWnt Signaling PathwayAspirinbeta CateninDecitabineaspirincell proliferationDecitabinemetastasisnon-small cell lung cancerSTAT3β-catenin

Identifiers

PMID35869624
PMCPMC9315258
OpenAlexW4286687099

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.